Table 2. Incidence of malignant pleural effusions caused by parental and KRAS -modulated tumour cell lines.
| n=206 |
MPE |
P value | ||
|---|---|---|---|---|
| no | yes | % | ||
| LLC shC (G12C) | 3 | 11 | 79 | c |
| LLC shKras | 10 | 2 | 17 | 0.0048 |
| MC38 shC (G13R) | 0 | 11 | 100 | C |
| MC38 shKras | 10 | 4 | 29 | 0.0005 |
| AE17 shC (G12C) | 1 | 10 | 91 | c |
| AE17 shKras | 11 | 0 | 0 | <0.0001 |
| FULA shC (G12V, Q61R/H) | 1 | 8 | 89 | c |
| FULA shKras | 8 | 1 | 11 | 0.0034 |
| B16F10 pC (WT) | 10 | 1 | 9 | c |
| B16F10 pΔKras2A | 0 | 10 | 100 | <0.0001 |
| B16F10 pΔKras2B | 1 | 12 | 92 | <0.0001 |
| PANO2 pC (WT) | 14 | 2 | 13 | c |
| PANO2 pΔKras2A | 0 | 12 | 100 | <0.0001 |
| PANO2 pΔKras2B | 4 | 12 | 75 | 0.0010 |
| SKMEL2 pC (WT) | 9 | 0 | 0 | c |
| SKMEL2 pΔKras2B | 2 | 8 | 80 | 0.0007 |
| HEK293T pC (WT) | 9 | 0 | 0 | c |
| HEK293T pΔKras2B | 2 | 7 | 78 | 0.0023 |
AE17, C57BL/6 malignant pleural mesothelioma; B16F10, C57BL/6 malignant skin melanoma; FULA, FVB urethane-induced lung adenocarcinoma; HEK293T, human embryonic kidney cells; LLC, C57BL/6 Lewis lung carcinoma; MC38, C57BL/6 colon adenocarcinoma; PANO2, C57BL/6 pancreatic adenocarcinoma; SKMEL2, human malignant skin melanoma; WT, wild-type.
Shown is number of mice (n) that developed dry pleural carcinomatosis (no MPE;<100 μl pleural fluid) and number (n) and percentage (%) of mice that developed MPE (≥100 μl pleural fluid). P<0.0001 for overall comparison by χ2 test. P, probability values for comparison with parental control cells (c) by Fischer's exact tests.